StereotaxisSTXS
About: Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Employees: 139
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
2,469% more call options, than puts
Call options by funds: $822K | Put options by funds: $32K
185% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 13
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
14% more capital invested
Capital invested by funds: $82.4M [Q3] → $93.8M (+$11.5M) [Q4]
1% more funds holding
Funds holding: 83 [Q3] → 84 (+1) [Q4]
0.93% more ownership
Funds ownership: 47.69% [Q3] → 48.62% (+0.93%) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for STXS.
Financial journalist opinion
